

**Table 1: Clinico-pathological characteristics of the 19 CTCL patients including data regarding response to Peg-doxo monotherapy, adverse effects and follow-up.**

Pt	Age	Duration disease (mo.s)	Sex	Lymphoma type and stage	Pre-Caelyx treatment	Lesions	Type of lesions	Max. Response (mo.s)	Response	Toxicity (grade)	Event (mo.s)	PD (mo.s)	Final Status	Follow-up (mo.s)
1	67	19	M	MF IB	Topical steroids, IFN	Multiple generalized	Plaques	4	VGPR	No	No	No	Alive VGPR	3.9
2	64	120	F	MF IB	CHOP, DHAP, 2CdA, AutoBMT, gemcitabine	Multiple generalized	Patches	5	CR	No	No	No	Alive SD	33.8
3	29	20	F	MF IIA	IFN +PUVA; radiotherapy	Single	Plaque	2	VGPR	Yes (III)	No	No	Alive CR	30.6
4	41	102	M	MF IIA	IFN + PUVA; IFN + ATRA; radiotherapy	Multiple localized	Patches	3	PR	Yes (II)	No	No	Alive PR	33.1
5	71	46	M	MF II B	PUVA, retinoids, gemcitabine	Multiple generalized	Nodules	3	CR	Yes (I)	Yes (14.2)	Yes (14.2)	Alive PD	18.6
6	73	66	F	MF II B	PUVA, retinoids, gemcitabine	Multiple generalized	Nodules	3	CR	No	Yes (19.1)	Yes (19.1)	Alive PR	22.6
7	77	252	M	MF foll. II B	Topical steroid, gemcitabine	Multiple generalized	Nodules	5	CR	No	Yes (26.1)	Yes (26.1)	DOD	33.8
8	68	43	F	MF foll. II B	PUVA, retinoids	Multiple generalized	Nodules	2	PR	No	Yes (19.8)	Yes (19.8)	Alive SD	22.9
9	37	43	F	MF foll. II B	PUVA, retinoids	Multiple generalized	Nodules	3	CR	No	Yes (18.2)	Yes (18.2)	Alive CR	20.6
10	63	4	M	MF erythro. III A	Topical and systemic steroid	Multiple generalized	Erythroderma	2	PD	No	Yes (1.9)	Yes (1.9)	Alive VGPR	17.0
11	62	118	M	Transf. CD30-large cell MF IV	PUVA, radiotherapy, gemcit., daunoxome	Multiple generalized	Nodules	3	CR	No	Yes (11.9)	Yes (11.9)	DNOD	26.4
12	66	2	M	Transf. CD30+large cell MF IV	Topical steroids; PUVA	Multiple generalized	Nodules	8	VGPR	No	No	No	Alive VGPR	9.1
13	62	70	M	Transf. CD30+large cell MF IV	Fludarabine, mitoxantrone	Multiple localized	Patches	5	CR	Yes (IV)	Yes (45.9)	No	DNOD	45.9
14	69	1	M	SS, IV	IFN	Multiple generalized	Erythroderma	6	mR	No	Yes (11.4)	Yes (11.4)	Alive VGPR	25.2
15	72	9	M	SS, IV	Fludarabine	Multiple generalized	Erythroderma	3	CR	No	Yes (12.8)	No	DNOD	12.8
16	84	3	M	SS, IV	Topical steroid	Multiple generalized	Erythroderma	6	SD	No	No	No	Alive mR	33.7
17	64	70	M	PTCL-U, IV	PUVA, gemcitabine, radiotherapy	Multiple generalized	Nodules	2	PR	Yes (II)	Yes (14.2)	Yes (14.2)	DOD	15.5
18	83	29	M	PTCL-U, IV	VNCOP-B, PUVA, IFN, chlorambucil	Multiple generalized	Plaques	2	VGPR	No	Yes (6.7)	No	DNOD	6.7
19	75	1	M	PTCL-U, IV	Topical steroid	Single	Nodules	3	VGPR	No	Yes (3.4)	No	DNOD	3.4